7月14日，科伦博泰生物盘中下跌3.17%，报497.0港元，成交额1.31亿港元。
消息面上，公司于7月10日完成583.8万股新H股配售，配售价每股470.20港元，较配售前收市价折让约8.52%，净筹约27.23亿港元。配售完成当日股价大涨8.74%至516.5港元，此后连续两个交易日出现技术性回调。配售完成后公司总股本增至约2.39亿股，母公司科伦药业仍持有约52.11%股权。所得款项将用于产品研发、临床试验及商业化推进。当前生物科技板块整体承压，信达生物跌0.28%、百济神州跌0.81%、康方生物跌0.89%、荣昌生物跌2.26%、三生制药跌3.98%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.